EXAMINE THIS REPORT ON AZELAPRAG AMGEN

Azelaprag was well tolerated in this review and in the least doses tested to this point in 227 topics, with a safety profile per the findings of prior phase 1 trials performed by Amgen.Potent cytochrome P450 3A4 and/or P-glycoprotein inhibitors could warrant AMG 986 dose reduction and will be coadministered with caution in people with coronary hear